Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance

摘要: Introduced more than 100 years ago, endocrine therapy is still the most important systemic for all stages of estrogen receptor (ER) -positive breast tumors. A major clinical problem limiting usefulness this tumor resistance, either de novo or acquired during course treatment. Relatively new discoveries emphasize complexity ER signaling and its multiple regulatory interactions with growth factor other kinase pathways. Both genomic (nuclear) nongenomic (membrane cytoplasmic) activities contribute to intimate cross-talk, which probably a fundamental in resistance. New targeted therapies, especially against epidermal receptor/HER-2 pathway, should be carefully evaluated (bio)logical strategies enable them exploited appropriately. strategy combining (particularly tamoxifen) these inhibitors, circumvent will discussed. We also open questions future challenges dynamic research field molecular biology from perspective.